Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies
Standard
Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies. / Sureda, Anna; Dreger, Peter; Bishop, Michael R; Kroger, Nicolaus; Porter, David L.
In: BONE MARROW TRANSPL, Vol. 54, No. 1, 01.2019, p. 17-25.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies
AU - Sureda, Anna
AU - Dreger, Peter
AU - Bishop, Michael R
AU - Kroger, Nicolaus
AU - Porter, David L
PY - 2019/1
Y1 - 2019/1
N2 - Relapse is now the major cause of treatment failure after allogeneic HSCT (alloHSCT). Many novel strategies to address this critical issue are now being developed and tested. At the 3rd International Workshop on Biology, Prevention, and Treatment of Relapse held in Hamburg, Germany in November 2016, international experts presented and discussed recent developments in the field. Some approaches may be applicable to a wide range of patients after transplant, whereas some may be very disease-specific. We present a report from the session dedicated to issues related to prevention and treatment of relapse of lymphoid malignancies after alloHSCT. This session included detailed reviews as well as forward-looking commentaries that focused on Hodgkin lymphoma, chronic lymphocytic leukemia and mantle cell lymphoma, diffuse large cell and follicular lymphoma, and multiple myeloma.
AB - Relapse is now the major cause of treatment failure after allogeneic HSCT (alloHSCT). Many novel strategies to address this critical issue are now being developed and tested. At the 3rd International Workshop on Biology, Prevention, and Treatment of Relapse held in Hamburg, Germany in November 2016, international experts presented and discussed recent developments in the field. Some approaches may be applicable to a wide range of patients after transplant, whereas some may be very disease-specific. We present a report from the session dedicated to issues related to prevention and treatment of relapse of lymphoid malignancies after alloHSCT. This session included detailed reviews as well as forward-looking commentaries that focused on Hodgkin lymphoma, chronic lymphocytic leukemia and mantle cell lymphoma, diffuse large cell and follicular lymphoma, and multiple myeloma.
KW - Congresses as Topic
KW - Germany
KW - Hematologic Neoplasms/prevention & control
KW - Hematopoietic Stem Cell Transplantation
KW - Hodgkin Disease/prevention & control
KW - Humans
KW - Lymphoma, Non-Hodgkin/prevention & control
KW - Multiple Myeloma/prevention & control
KW - Recurrence
KW - Transplantation, Homologous
U2 - 10.1038/s41409-018-0214-5
DO - 10.1038/s41409-018-0214-5
M3 - SCORING: Review article
C2 - 29795433
VL - 54
SP - 17
EP - 25
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 1
ER -